ETON Stock: Price, Earnings History and SEC Filings
Eton Pharmaceuticals, Inc. (ETON) last traded at $52.18, down 2.78% on the latest session and up 1.3% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $0.35 against an analyst estimate of $0.11, a beat of 218.2%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
ETON earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 13, 2026 | $0.35 | $0.11 | +218.18% |
| Mar 2026 | May 14, 2026 | $0.05 | $0.10 | -50.00% |
| Dec 2025 | Mar 19, 2026 | $0.05 | $0.12 | -58.33% |
| Sep 2025 | Nov 6, 2025 | $-0.07 | $0.13 | -153.85% |
ETON beat the analyst EPS estimate in 1 of its last 4 reported quarters. Source: Nasdaq.
How ETON reacts to earnings
Across its last 8 earnings releases, ETON moved 12.1% on average the next session, in either direction. It rose after 6 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-13 | After close | +44.26% |
| 2026-05-14 | After close | +1.00% |
| 2026-03-19 | After close | +7.46% |
| 2025-11-06 | After close | -11.70% |
| 2025-08-07 | After close | +12.32% |
| 2025-05-13 | After close | +0.29% |
| 2025-03-18 | Before open | -3.99% |
| 2024-11-12 | After close | +15.59% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
ETON financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $80M | -$5M | $10M | -5.8% | – |
| 2024 | $39M | -$4M | $943000 | -9.8% | – |
| 2023 | $32M | -$936000 | $7M | -3.0% | – |
| 2022 | $21M | -$9M | $5M | -42.4% | – |
| 2021 | $22M | -$2M | -$5M | -9.0% | – |
| 2020 | $39000 | -$28M | -$22M | -71717.9% | – |
| 2019 | $959000 | -$18M | -$19M | -1910.3% | – |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for ETON
- 8-K · Oct 14, 2026Material agreement, Acquisition or disposal completed, Financial statements and exhibits
- 8-K · Sep 28, 2026Other events, Financial statements and exhibits
- 10-Q · Aug 13, 2026
- 8-K · Aug 13, 2026Results of operations, Financial statements and exhibits
- 8-K · Aug 5, 2026Material agreement, Acquisition or disposal completed, Financial statements and exhibits
- 8-K · Aug 4, 2026Officer or director change
- 8-K · Jul 29, 2026Other events, Financial statements and exhibits
- 8-K · Jun 9, 2026Shareholder vote
- 8-K · May 19, 2026Material agreement, Acquisition or disposal completed, Financial statements and exhibits
- 10-Q · May 14, 2026
Insider filing activity
ETON insiders filed 4 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
ETON news
- Eton Pharmaceuticals stock has Q3 results dateNov 1, 2026 · ad-hoc-news.de
- Eton Pharmaceuticals to Report Third Quarter 2026 Financial Results on Thursday, November 5, 2026Oct 29, 2026 · finance.yahoo.com
- Eton Pharmaceuticals (ETON) Stock Still Looks Rich Despite Its New Seizure Drug LicenseOct 22, 2026 · finance.yahoo.com
About Eton Pharmaceuticals, Inc.
Eton Pharmaceuticals, Inc. (ETON) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in DE. Its fiscal year ends in December.